of the disorder are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%). 2 The most common presenting symptom is fatigue related to a normocytic anemia. The median hemoglobin value at diagnosis is 10 g/dL. 3 Many patients who fulfill the criteria of WM do not require immediate therapy because they are asymptomatic. 4 Virtually all patients have a preceding phase of IgM monoclonal gammopathy of undetermined significance (MGUS), but the clonal MGUS B cells already contain the molecular signature of a malignant clone.
Phenotypically, the cells arise from CD25 + CD22 +low activated B lymphocytes. 5 Patients under the age of 70 have a median survival in excess of 10 years; those 70-79, approximately 7 years; and those 80 or older, approximately 4 years. 6 The age-adjusted incidence rate for males was 0.92 per 100 000
person-years and for females was 0.30 per 100 000 person-years with an age-and sex-adjusted incidence of 0.57 per 100 000 personyears. There was no convincing evidence for a change in the incidence of WM over the past 50 years. 7 As a comparison, the incidence of amyloidosis is 0.8 per 100 000
person-years. 8 Incidence is higher in whites (4.1 per million per year) than in blacks (1.8 per million per year). 8 Waldenström patients had a positive family history of lymphoplasmacytic lymphoma or WM in 4.3%, and a family history was associated with poorer survival than the nonfamilial forms. 9 A study of monoclonal immunoglobulins showed that the M protein isotype in black and white patients was 2% and 16%
IgM, respectively. The median M protein concentration for blacks was 0.44 g/dL, whereas it was 1.2 g/dL in whites. Black patients less commonly have IgM monoclonal gammopathy compared with white patients. 10 Median age at diagnosis is 63 years for blacks and 73 for whites, 11 with blacks having a shorter survival than whites with WM. survival. The hazard ratio for death for WM patients age 80 or greater was 6.99, compared with a reference group less than age 50. 6 The presence of the monoclonal IgM protein adds a unique dimension to the disorder because it can result in hyperviscosity syndrome, 12 peripheral neuropathy 13 , hemolytic anemia, 14 and immune complex vasculitis. 15 The 10-year survival rate is now 66%. 16 In a population-based study of 1555 patients with WM and lymphoplasmacytic lymphoma, 5-year relative survival improved significantly over time from 57% in 1980 to 78% in 2005. Survival improvements were seen in all age groups, although increasing age was associated with inferior survival. 17 The management of peripheral neuropathy associated with IgM monoclonal protein (chronic inflammatory demyelinating polyneuropathy) remains frustrating for clinicians. Amyloidosis needs to be excluded when an IgM monoclonal protein is seen with neuropathy, particularly if the light-chain isotype is λ. In immunoglobulin light chain amyloidosis, 5% have an IgM monoclonal protein. 18 The mechanism of the neuropathy is thought to be demyelination due to direct binding of the antibody to myelin-associated glycoprotein. 19 The treatment of IgM-associated peripheral neuropathy can be similar to that of WM. In one study, 20 4 of 5 patients treated with fludarabine and rituximab showed a major hematologic response, with markedly improved neurologic symptoms and electrophysiologic findings. No relapses were reported during a follow-up of 12-45 months.
With the introduction of PET-CT imaging, extramedullary Waldenström has been recognized and carries with it a shorter progression-free survival (PFS) and OS. Rituximab appeared to have little impact in improving these adverse outcomes. Nucleoside analogs, however, did improve outcomes in this subgroup with extramedullary disease. 21 
| DIAGNOSIS
In the original description of WM, Jan Gösta Waldenström 22 described 2 patients with oronasal bleeding (hyperviscosity), lymphadenopathy, anemia, thrombocytopenia, and an elevated sedimentation rate. The disorder is a lymphoplasmacytic lymphoma 1 with a monoclonal pentameric IgM protein. 23 Bone marrow and lymph nodes are infiltrated with pleomorphic B-lineage cells at different stages of maturation. 24 The bone marrow pattern is predominantly intertrabecular. 1 Many patients who fulfill all other criteria for the diagnosis have a presymptomatic phase and may not require therapy. 25 The cells express pan B-cell markers (eg, CD19, CD20) and typically test negative for CD3 and CD103. 26 The 6q genetic deletion is present in 42% of patients and is associated with an adverse prognosis. 27 Deletion of 6q and 11q and trisomy 4 had adverse effects on survival. 28 Whole-genome sequencing of lymphoplasmacytic cells from patients with WM has been reported. 29 A recurring sequence variant at position 38 182 641 in chromosome 3p22.2 was identified. A singlenucleotide change from T to C in the MYD88 gene resulted in a leucine-to-proline change at amino acid position 265. Together, these studies demonstrate an important somatic variant in the malignant are not used to determine prognosis. Table 2 gives the currently accepted international staging system for WM. 50 The 5 criteria shown in Table 2 The International Prognostic Scoring System for WM is to be used only for patients who require treatment. The system should not be used to determine whether a patient requires intervention; this determination continues to be a clinical decision. 4 The value of this scoring system has been validated in patients treated with rituximab. 56 Serial measurements of β 2 microglobulin are not useful in monitoring therapy.
Because patients with WM have an indolent disease course and often are of an advanced age, nearly half of all patients succumb to diseases of the elderly, unrelated to WM. The impact of age on OS was investigated in 238 patients with WM. 57 The poorest survival of patients older than 65 years at diagnosis was attributable to the higher number of nonWM-related deaths. Cause-specific survival has been introduced as an important outcome measure. This statistical technique censors patients who die of causes unrelated to the malignancy and accounts for the competing risks of death that these patients face. 53 In a competing risk survival analysis, 23% of deaths were unrelated to WM, and 40% of patients >75 years do not die of WM. 58 Patients with WM have greater overall risk of a second malignancy that is 1.69 times higher than expected (P = .002). 59 When compared with the general population, patients with WM appear to have a higher risk of large cell lymphoma, myelodysplasia, and brain cancer. 60, 61 Therapy related myeloid neoplasms occur in 2.7% of patients. 62 4 | MANAGEMENT
| Hyperviscosity syndrome
Hyperviscosity syndrome is seen in an ever-decreasing proportion of patients with WM because WM is being diagnosed earlier. 63 Symptomatic hyperviscosity is rare in patients with an IgM concentration <4000 mg/dL, and viscosity measurements are not required in patients whose IgM levels are below that threshold. 64 The symptoms of hyperviscosity are primarily due to shear forces that rupture unsupported venous channels. As a consequence, the presentation generally includes epistaxis, gingival bleeding, and visual changes due to retinal hemorrhage. Central nervous system findings, including dizziness, light-headedness, and generalized fatigue, are nonspecific and must be confirmed with measures of serum viscosity. Reference serum viscosity is 1.8; water has a viscosity of 1. Hyperviscosity syndrome should not be suspected unless the serum viscosity exceeds 4.
65
When hyperviscosity is present, plasma exchange should be considered a temporizing measure until systemic therapy successfully lowers the tumor mass and thereby reduces the IgM protein concentration in the serum.
66-68

| Systemic chemotherapy to reduce tumor mass
Rituximab is a widely available treatment for the management of WM. Its lack of long-term toxicity, lack of impact on the mobilization of peripheral blood stem cells, and nonmyelosuppressive treatment profile have led to its incorporation in most therapeutic regimens for this disorder.
However, rituximab alone is generally a poor choice for patients in need of therapy. Including both minor (25%-50% reduction of M protein) and objective (>50% reduction of IgM protein) responses, the response rate to rituximab (<55%) is inferior to virtually every other reported combination regimen. 69 A meta-analysis confirmed that a greater response was produced with combination therapy of 2 or more drugs than with rituximab monotherapy (73% vs 44%). 70 An analysis of the impact of rituximab on depth of response and the impact of response depth on outcome has been reported. 71 No difference in PFS was seen when comparing patients achieving a complete response with those achieving a very good partial response.
Age, hemoglobin level, IgM level, platelet count, and β 2 microglobulin level were not predictive of response depth. A complete or very good partial response was associated with significantly longer PFS.
Rituximab is inferior to single-agent chemotherapy with alkylating agents such as chlorambucil 72 and cladribine. 73, 74 Single-agent rituximab is used at Mayo Clinic for patients who present with only a 50 Used with permission. a One point is assigned for each positive factor and the risk score is the sum of points.
peripheral neuropathy related to the IgM anti-myelin-associated glycoprotein activity, with no concomitant evidence of symptomatic lymphoma. 75 In all others multi agent therapy is used.
Use of rituximab as a single agent is associated with the risk of "flare" for many patients. 76 In this phenomenon, the initiation of rituximab treatment results in a transient rise in the level of IgM, which can produce an increase of serum viscosity. This flare is seen less frequently when rituximab is combined with cytotoxic chemotherapy. 77 In some trials, rituximab is delayed until the second cycle to allow cytotoxic therapy to reduce IgM levels and reduce the risk of hyperviscosity associated with the introduction of rituximab.
The use of maintenance rituximab therapy is controversial. However, in a retrospective review comparing patients who were and were not selected for rituximab maintenance therapy, 78 improved PFS and OS were seen in patients receiving maintenance therapy, independent of previous treatment status, although an increased number of infections was observed in patients on maintenance therapy. At this time, insufficient evidence supports the use of maintenance rituximab. 79 Rituximab is not the only monoclonal antibody that has been used in WM. Ofatumumab, an antiCD20 monoclonal human antibody, has shown activity in WM. 80 In a trial of 37 Waldenström patients receiving ofatumumab 15 (41%) achieved a partial response, 7 (19%) a minor response. All 37 patients had at least one adverse event. 81 A phase III trial of chlorambucil vs fludarabine in WM reported significantly improved PFS with fludarabine. OS was improved with fludarabine (median survival was not reached in the fludarabine arm vs 69.8 months in the chlorambucil arm; P = .01). 82 Chlorambucil is rarely used today in the United States.
A 10-year follow-up data are available on the use of single-agent fludarabine in the treatment of WM. 83 Durable responses have been seen with fludarabine, even as a single agent. In that study, 98 patients with no more than one risk factor had an 8-year survival estimate of 55%, compared with 33% among the 51 patients with 2 risk factors (P < .001). By comparison, the 20 patients with more than 2 risk factors had an 8-year survival estimate of only 5% (P < .003). In a separate study, 84 43 patients with untreated or previously treated WM received rituximab, fludarabine, and cyclophosphamide (FCR). Only β 2 microglobulin levels were predictive of the frequency of response. In total 19 patients (44%) had long-term neutropenia. Of 3 patients (7%) had development of myelodysplastic syndrome. The overall response rate was 79%, with complete remission in 21%. Event-free survival was 77 months. 85 The rituximab-fludarabine-cyclophosphamide treatment was active and led to rapid disease control. Fludarabine was reported to be associated with an infection rate of 33%. 86, 87 Fludarabine use has fallen significantly in the United States but remains a popular choice in the European Union. Fludarabine is not recommended as a first-line regimen due to its myelosuppressive and immunosuppressive properties. 88 The purine analog, pentostatin, acts as an inhibitor of adenosine deaminase. It has been combined with rituximab and cyclophosphamide in WM. Twenty-five patients (21 previously untreated) received this regimen for six 22-day cycles. Two-year PFS was 83.6% with no deaths at 2 years. Purine nucleoside analogs
should not be forgotten in the salvage therapy of WM. Long term myelosuppression with FCR and the higher infection rate with fludarabine make it a consideration for third line therapy. 89, 90 Today, most patients with WM are treated with combination chemotherapy. Cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP) treatment has been reported by 2 research groups as having at least a 90% response rate. 91, 92 However, the value of adding doxorubicin in this disease is uncertain.
Rituximab treatment combined with cyclophosphamide (orally) and dexamethasone has been reported, with a response rate of 83% and minimal toxicity. 93 Two-year PFS was 67%; 2-year disease-specific survival was 90%.
In an updated final analysis in 72 patients treated with rituximab cyclophosphamide and dexamethasone, the response rate on an intent-to-treat basis was 83%. Median PFS was 35 months. Median OS was 95 months. 94 This 3-agent combination is currently an alternative regimen for first-line therapy if the disease burden is low, based on Mayo Clinic mSMART guidelines.
Stem cell transplantation (ASCT) has been shown to produce durable responses with a treatment-related mortality rate of 3.8%.
95
Good outcomes are seen with high-dose treatment; 5-year PFS and OS rates were 39.7% and 68.5%, respectively. 95 The favorable outcome seen with high-dose therapy is related in part to the low proliferative rate of these malignant cells and the lack of unfavorable cytogenetic abnormalities as −17p. 
98
Autologous stem cell transplantation has been reported to improve both OS and event-free survival in previously treated and untreated patients. 99 Among 158 patients, the median reported survival was 9.2 years. The response rate reported is 90%; the relapsefree survival rate is 65% at 3 years. 100 The introduction of novel agents for multiple myeloma has provided benefits for patients with WM. Rituximab combined with thalidomide 101 produced a 72% response rate, and rituximab combined with lenalidomide 102 produced a 50% response rate, although lenalidomide aggravated anemia in a large proportion of patients. Thalidomide and lenalidomide have activity, although the subclinical neuropathy 103 that exists in patients with WM predisposes them to enhanced neurotoxicity from thalidomide.
Bortezomib has been shown to have high levels of activity in the management of relapsed WM in schedules of twice weekly in 2 of 3 weeks 102,104 and of once weekly in 4 of 5 weeks, 105 with response rates ranging from 81% to 96%. In newly diagnosed patients, weekly treatment with bortezomib and rituximab resulted in a better-thanminimal response in 23 of 26 patients and a 1-year event-free survival rate of 79%. 106 Most importantly, no grade 3 or 4 neuropathy was seen with the weekly bortezomib schedule. The European Myeloma
Network reported outcomes of bortezomib, rituximab, and dexamethasone in previously untreated symptomatic patients. Rituximab was delayed to cycles 2 and 5 to reduce the risk of flare. No patient required plasma exchange for flare. The response rate was 85%, the median PFS was 42 months, and the 3-year OS was 81%. 107 Peripheral neuropathy was seen in 46%. 108 Bortezomib-rituximab-dexamethasone is a reasonable choice for front-line therapy, but attention to early neurotoxicity is required to avoid permanent impairment. Bortezomib also has reported activity in cold agglutinin disease with an overall response rate of 32%. 109 In view of the high neuropathy rates, the less neurotoxic proteosome inhibitor, carfilzomib, was combined with rituximab and dexamethasone in patients not previously treated with the combination of rituximab and bortezomib. The overall response rate was 87%, with 36% having at least a very good partial response. At 2 years, 65%
were progression-free. The peripheral neuropathy rate and cardiomyopathy rates were both 3%. 110 This combination has also been used for the management of relapsed disease. 111 The oral proteosome inhibitor, ixazomib, was combined with dexamethasone and rituximab, 26 patients were enrolled with an overall response rate of 96%, and a major response rate of 77%. The median time to response was 8 weeks.
112
The mammalian target of rapamycin inhibitor, everolimus, has been shown to produce a response rate of 70% in previously treated WM, although mouth sores and pulmonary toxicity occurred in 8% 115 Everolimus has been combined with bortezomib and rituximab followed by everolimus maintenance.
A minor response or better was reported in 89%, PR or better 53%.
Median PFS was 21 months. Grade 3 or 4 toxicity occurring in over 10% was hematologic only. 116 Histone deacetylase inhibitors also have shown activity in WM. 117 As a single agent, panobinostat resulted in a minimal response or better in 47%. The median PFS was 6.6 months.
118
In the prospective randomized study of bendamustine plus rituximab compared with R-CHOP in low-grade lymphoma, a subset analysis identified 41 patients with WM, of whom 22 received bendamustine and rituximab, and 19 received R-CHOP. 119 In both groups, the response rate was 95%, but median PFS was significantly The risk of progression appears to be lower in patients treated with bendamustine-rituximab or bortezomib-dexamethasone-rituximab when compared with cyclophosphamide-dexamethasone-rituximab. 122 At Mayo Clinic 60 patients receiving rituximab bendamustine were compared with 100 patients receiving rituximab favoring bendamustine, outcomes independent of MYD88 status. 123 Rituximab-bendamustine is the Mayo Clinic preferred induction regimen for newly diagnosed WM due to its ease of use and low rates of nonhematologic adverse events. In an open-label sub-study that was multi-center and phase 3, 31 patients, all of whom were rituximab refractory with a median age of 67, were enrolled. Overall response rate was 71%, PFS at 18 months was 86%, and OS was 97%. 129 A trial of 30 patients who were newly diagnosed and received ibrutinib was reported. The major response rate was 80% with no difference between patients with wild-type or mutated MYD 88. Atrial arrhythmias were seen in 10%. 130 In treatment naïve patients overall (minor or more than minor) and major (partial or greater than partial) responses for all patients were 100% and 83%, respectively. 131 In relapsed Waldenström a phase 3 trial randomized patients to ibrutinib with rituximab to rituximab alone at 30 months, the PFS rate was 82% with ibrutinibrituximab vs 28% with placebo-rituximab. 132 Since macroglobulinemia cells highly express Bcl-2 venetoclax is a logical therapy for this disorder.
| IBRUTINIB
133,134 Figure 1 shows the Mayo Clinic algorithm for the recommended management of patients with newly diagnosed WM. Figure 2 illustrates treatment recommendations for patients with relapsing WM, based on consensus criteria developed by the WM treatment and research group at Mayo Clinic. 135 The National Comprehensive Cancer Network has recently published its consensus recommendations on diagnosis and therapy of WM. 136 Recent consensus reviews on WM are available. 
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